Armata Pharmaceuticals Inc
ARMP6.240USD
+0.080+1.30%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
226.07MMarket Cap
LossP/E TTM
More Details of Armata Pharmaceuticals Inc Company
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The Company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
Armata Pharmaceuticals Inc Info
Ticker SymbolARMP
Company nameArmata Pharmaceuticals Inc
IPO dateMay 20, 1994
CEOBirx (Deborah L)
Number of employees60
Security typeOrdinary Share
Fiscal year-endMay 20
Address5005 Mcconnell Ave
CityLOS ANGELES
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code90066
Phone13106652928
Websitehttps://www.armatapharma.com/
Ticker SymbolARMP
IPO dateMay 20, 1994
CEOBirx (Deborah L)
Company Executives of Armata Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Pierre Kyme, Ph.D.
Dr. Pierre Kyme, Ph.D.
Chief Business Officer
Chief Business Officer
2.99K
+509.16%
Dr. Deborah L. Birx, M.D.
Dr. Deborah L. Birx, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Joyce Allaire
Ms. Joyce Allaire
Investor Relations
Investor Relations
--
--
Dr. Joseph M. Patti, Ph.D.
Dr. Joseph M. Patti, Ph.D.
Independent Director
Independent Director
--
--
Dr. Todd C. Peterson, Ph.D.
Dr. Todd C. Peterson, Ph.D.
Independent Director
Independent Director
--
--
Dr. Odysseas D. Kostas, M.D.
Dr. Odysseas D. Kostas, M.D.
Independent Director
Independent Director
--
--
Dr. Sarah J. Schlesinger, M.D.
Dr. Sarah J. Schlesinger, M.D.
Independent Director
Independent Director
--
--
Mr. Jules A. Haimovitz
Mr. Jules A. Haimovitz
Independent Director
Independent Director
--
--
Ms. Robin C. Kramer
Ms. Robin C. Kramer
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. David House
Mr. David House
Principal Financial Officer, Senior Vice President - Finance
Principal Financial Officer, Senior Vice President - Finance
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Pierre Kyme, Ph.D.
Dr. Pierre Kyme, Ph.D.
Chief Business Officer
Chief Business Officer
2.99K
+509.16%
Dr. Deborah L. Birx, M.D.
Dr. Deborah L. Birx, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Joyce Allaire
Ms. Joyce Allaire
Investor Relations
Investor Relations
--
--
Dr. Joseph M. Patti, Ph.D.
Dr. Joseph M. Patti, Ph.D.
Independent Director
Independent Director
--
--
Dr. Todd C. Peterson, Ph.D.
Dr. Todd C. Peterson, Ph.D.
Independent Director
Independent Director
--
--
Dr. Odysseas D. Kostas, M.D.
Dr. Odysseas D. Kostas, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Innoviva Inc
68.88%
The Vanguard Group, Inc.
0.82%
Geode Capital Management, L.L.C.
0.29%
Edgewood Management LLC
0.27%
Pastagia (Mina M.D.)
0.17%
Other
29.58%
Shareholders
Shareholders
Proportion
Innoviva Inc
68.88%
The Vanguard Group, Inc.
0.82%
Geode Capital Management, L.L.C.
0.29%
Edgewood Management LLC
0.27%
Pastagia (Mina M.D.)
0.17%
Other
29.58%
Shareholder Types
Shareholders
Proportion
Corporation
68.88%
Investment Advisor
1.23%
Investment Advisor/Hedge Fund
0.73%
Individual Investor
0.27%
Hedge Fund
0.11%
Other
28.78%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
42
758.32K
2.17%
--
2025Q3
43
758.32K
2.22%
+24.50K
2025Q2
44
733.82K
2.16%
-6.55K
2025Q1
42
740.37K
4.05%
-724.52K
2024Q4
45
1.39M
4.14%
+5.16K
2024Q3
45
1.38M
4.34%
-20.83K
2024Q2
44
1.40M
4.38%
-19.96K
2024Q1
45
1.42M
4.03%
-32.91K
2023Q4
46
1.30M
4.04%
+7.01K
2023Q3
47
1.29M
3.73%
+96.20K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Innoviva Inc
25.08M
69.22%
--
--
Aug 11, 2025
The Vanguard Group, Inc.
260.07K
0.72%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
104.55K
0.29%
-1.29K
-1.22%
Jun 30, 2025
Edgewood Management LLC
100.00K
0.28%
--
--
Jun 30, 2025
Pastagia (Mina M.D.)
61.08K
0.17%
--
--
Apr 17, 2025
Bridgeway Capital Management, LLC
44.68K
0.12%
--
--
Jun 30, 2025
Renaissance Technologies LLC
38.90K
0.11%
+300.00
+0.78%
Jun 30, 2025
State Street Investment Management (US)
40.30K
0.11%
--
--
Jun 30, 2025
Seacrest Wealth Management, LLC
34.95K
0.1%
--
--
Jun 30, 2025
GSB Wealth Management, LLC
30.00K
0.08%
+30.00K
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Armata Pharmaceuticals Inc?
The top five shareholders of Armata Pharmaceuticals Inc are:
Innoviva Inc holds 25.08M shares, accounting for 69.22% of the total shares.
The Vanguard Group, Inc. holds 260.07K shares, accounting for 0.72% of the total shares.
Geode Capital Management, L.L.C. holds 104.55K shares, accounting for 0.29% of the total shares.
Edgewood Management LLC holds 100.00K shares, accounting for 0.28% of the total shares.
Pastagia (Mina M.D.) holds 61.08K shares, accounting for 0.17% of the total shares.
Innoviva Inc holds 25.08M shares, accounting for 69.22% of the total shares.
The Vanguard Group, Inc. holds 260.07K shares, accounting for 0.72% of the total shares.
Geode Capital Management, L.L.C. holds 104.55K shares, accounting for 0.29% of the total shares.
Edgewood Management LLC holds 100.00K shares, accounting for 0.28% of the total shares.
Pastagia (Mina M.D.) holds 61.08K shares, accounting for 0.17% of the total shares.
What are the top three shareholder types of Armata Pharmaceuticals Inc?
The top three shareholder types of Armata Pharmaceuticals Inc are:
Innoviva Inc
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
Innoviva Inc
The Vanguard Group, Inc.
Geode Capital Management, L.L.C.
How many institutions hold shares of Armata Pharmaceuticals Inc (ARMP)?
As of 2025Q4, 42 institutions hold shares of Armata Pharmaceuticals Inc, with a combined market value of approximately 758.32K, accounting for 2.17% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.04%.
What is the biggest source of revenue for Armata Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Armata Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
